Clinical trials
Recurrence Tumor clinical trials
Below are recruiting recurrence tumor clinical trials, each written for real people, not researchers. We’re tracking 182 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT07444814RecruitingPhase 1
HWK-007 for advanced solid tumors
This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.
Little Rock, ArkansasAges 18 years+ - NCT06469008RecruitingPhase 1
Study of BL-B16D1 for advanced head and neck cancer and other solid tumors
This study tests a new drug, BL-B16D1, for people with advanced head and neck cancer or other solid tumors that have not been helped by standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06437522RecruitingPhase 2
New drug combo for recurrent head and neck cancer
This trial tests a new drug combination (BL-B01D1 plus a PD-1 inhibitor) for people with advanced head and neck cancer or other solid tumors that have come back or spread. It aims to see if the treatment can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06006169RecruitingPhase 2
Study of new drugs for head and neck cancer and other solid tumors
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT06126276RecruitingPhase 2
Testing neratinib with or without palbociclib for HER2+ solid tumors
This trial tests two targeted drugs—neratinib alone or with palbociclib—for people with HER2-positive solid tumors (other than breast cancer) that have returned or not gone away. The goal is to see if blocking HER2 and CDK4/6 can shrink or slow the tumor.
Birmingham, AlabamaAges 18 years+ - NCT04434040RecruitingPhase 2
Atezolizumab and sacituzumab to prevent breast cancer return
This trial tests two medicines after surgery and chemotherapy to help lower the risk that triple-negative breast cancer comes back. It’s for people whose cancer still showed “residual” invasive disease after neoadjuvant (before-surgery) chemotherapy, and whose blood test shows traces of tumor DNA.
San Francisco, CaliforniaAges 18 years+ - NCT07668869Recruiting
Electric fields with targeted radiation vs. alone for recurrent brain cancer
This trial tests whether adding a precise, MRI-guided radiation treatment to tumor-treating electric fields (TTFields) can help people with recurrent glioblastoma. You may qualify if your tumor has come back 1 to 3 times after standard therapy and you haven't had certain prior treatments.
BydgoszczAges 18 years+ - NCT07560865RecruitingPhase 1
New Cell Therapy for Recurring Brain Cancer
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
Minneapolis, MinnesotaAges 18–75 - NCT05408897Recruiting
Blood test to predict risk after surgery for high-risk GIST
This study uses a “liquid biopsy” blood test to look for leftover cancer signals after surgery. It aims to predict how well treatment will work and how likely the cancer is to come back in people with high-risk GIST.
Beijing, Beijing MunicipalityAges Any age - NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15 years+ - NCT06725173Recruiting
Retinoblastoma genetics and tumor spread study
This study looks at gene changes in retinoblastoma to understand why some tumors spread outside the eye. It may help find better ways to predict and treat the disease.
Seattle, WashingtonAges Any age - NCT07004582Recruiting
Lab study using mini-tumors to test prostate cancer treatments
This trial uses leftover tumor tissue from biopsies or brachytherapy to grow mini-tumors in the lab. Researchers want to test different treatments on these mini-tumors to find the best options for patients with high-risk or recurrent prostate cancer.
Heerlen, LimburgAges 18 years+ - NCT06157060Recruiting
Predicting liver cancer return after surgery with a blood test
This trial is for people with early-stage liver cancer who are scheduled for surgery. It uses a simple blood test to look for tiny bits of tumor DNA after treatment, which may help predict if the cancer will come back.
Foshan, GuangdongAges 18–75 - NCT06856213RecruitingPhase 2
Cetuximab with or without weekly paclitaxel for head and neck cancer
This study tests whether adding the chemotherapy drug paclitaxel (Taxol) to the targeted therapy cetuximab (Erbitux) is more effective than cetuximab alone for head and neck cancer that has progressed after initial immunotherapy and chemotherapy. Researchers want to see if the combination can help shrink tumors or slow the disease.
Santiago de Compostela, A CoruñaAges 18 years+ - NCT06495554Recruiting
Danish vulva cancer recurrence study
This study looks at how vulva cancer returns (recurrence) over time. It aims to improve follow-up care for people who have had this type of cancer.
Aarhus NAges 18 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Birmingham, AlabamaAges 1–21 - NCT04055649RecruitingPhase 2
Test of ONC201 and weekly paclitaxel for platinum-resistant ovarian cancer
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Detroit, MichiganAges 18 years+ - NCT04519151RecruitingPhase 2
Pembrolizumab plus lenvatinib for ovarian cancer that returned
This Phase 2 trial tests whether pembrolizumab plus lenvatinib can shrink ovarian cancer that has come back after platinum chemotherapy. You may be eligible if your cancer returned after a certain “time off” from prior treatment and you meet key health and safety requirements.
Ramat GanAges 18 years+ - NCT05521698RecruitingPhase 1
Bicalutamide study for early bladder cancer in men
This trial tests whether bicalutamide can help men with non-muscle invasive bladder cancer (an early form that hasn’t spread into muscle). It is a Phase 1 study, meaning the main goal is to see how safe it is and learn how it behaves in the body for this cancer type.
Tucson, ArizonaAges 18 years+ - NCT06061705Recruiting
Finding markers in patients with head and neck cancer on immunotherapy
This trial looks for specific signs in your blood and tumor tissue that may show how well immunotherapy is working for recurrent or metastatic head and neck cancer. It aims to help doctors personalize treatment in the future.
ParisAges 18 years+
Hear when a new Recurrence Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrence tumor?
- Yes. Clin2 currently lists 182 recruiting recurrence tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrence tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrence tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.